SEC Form 4 · accession 0001179110-17-002985
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy M Mayleben
Officer — President & CEO · Director
Period of report
Feb 21, 2017
Accepted (ET)
Feb 22, 2017 · 6:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $24.42 | Feb 21, 2017 | A | 171,100 | A | — | Feb 21, 2027 | Common Stock | 171,100 | 171,100 | D |
Explanation of responses
- F1The options vest over a four (4) year period in equal quarterly installments, the first of which will be on May 21, 2017.